secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXICURE, INC. (XCUR)
CIK:        0001698530
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001698530-22-000085
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exicure reports Q3 loss $5.2M; wind-down & going concern; $5.4M PIPE pending vote
--------------------------------------------------------------------------------

- Net loss $5.2M vs $23.5M; revenue $2.0M vs $(3.7)M due to AbbVie collaboration adjustment.
- Cash $16.8M (down from $48.3M Dec 2021); expects to fund into Q2 2023; substantial doubt about going concern; may need bankruptcy if PIPE fails.
- Private placement with CBI USA: 3.4M shares at $1.60, ~$5.4M gross; CBI to hold 50.4% after close; shareholder vote Dec 15, 2022.
- Company winding down preclinical programs, cut 66% workforce, suspended all R&D; seeking out-license for cavrotolimod and SCN9A program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1698530/000169853022000085/0001698530-22-000085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1698530/000169853022000085/xcur-20221114.htm
  HTML page:      https://secwatch.observer/filing/0001698530-22-000085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer